Chemotherapy with or without PIPAC for stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding a special type of chemotherapy sprayed directly into the abdomen (PIPAC) to standard chemotherapy is safer and works better for stomach cancer that has spread only to the lining of the abdomen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have stomach cancer or cancer where the stomach meets the esophagus (Siewert type III) that is a type called adenocarcinoma or ring-cell carcinoma
- Your cancer has spread only to the lining of the abdomen (peritoneal cavity) and the spread is limited (PCI less than 16)
- Your tumor does not have the HER2 protein (HER2-negative)
- You are healthy enough for daily activities (ECOG score 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a special type of chemotherapy delivered as a mist during surgery (PIPAC) can help prevent the spread of stomach cancer. It is for people with advanced but not yet metastatic stomach cancer who have not had prior treatment.
This trial looks at a way to give chemotherapy into the abdomen (through a small tube during laparoscopy) for certain stomach cancers. It aims to see whether this approach improves cancer control and surgical outcomes for people whose tumors can potentially be removed.
This trial studies a combination treatment for stomach cancer that has spread to the lining of the abdomen. It uses a special way to deliver heated chemotherapy directly into the abdomen, along with an immunotherapy drug that helps your immune system attack the cancer.
This trial combines heated chemotherapy directly into the abdomen (HIPEC) with standard chemotherapy and an immunotherapy drug to treat advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a treatment called PIPAC (medicine delivered into the abdomen through a small scope) along with “multimodal” therapy, including chemotherapy, for stomach cancer that has spread only in the lining of the abdomen in limited amounts. It may help control the cancer and prevent progression after surgery.
This Phase 1 trial tests PIPAC, a way to deliver anti-cancer medicine directly into the abdomen using a minimally invasive procedure. It is for people with peritoneal spread from certain cancers to see whether this approach is safe and potentially helpful.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.